Adagio Medical Holdings, Inc. (ADGM)
| Market Cap | 15.18M -27.4% |
| Revenue (ttm) | n/a |
| Net Income | -24.37M |
| EPS | -1.33 |
| Shares Out | 22.21M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,743,269 |
| Open | 0.7387 |
| Previous Close | 0.7320 |
| Day's Range | 0.5271 - 0.7387 |
| 52-Week Range | 0.3630 - 2.5820 |
| Beta | -0.15 |
| Analysts | Strong Buy |
| Price Target | 3.33 (+387.2%) |
| Earnings Date | Aug 14, 2026 |
About ADGM
Adagio Medical Holdings, Inc., a medical technology company, focuses on the development and commercialization of ablation technologies for the treatment of cardiac arrhythmias. It offers treatment for cardiac arrhythmias, including atrial fibrillation, and ventricular tachycardia. The company’s product portfolio includes iCLAS atrial ultra-low temperature ablation (ULTA) catheter and system; vCLAS ventricular ULTC catheter; and Cryopulse pulsed field cryoablation catheters. Adagio Medical Holdings, Inc. was founded in 2011 and is headquartered ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for ADGM stock is "Strong Buy." The 12-month stock price target is $3.33, which is an increase of 387.20% from the latest price.
News
Adagio Medical treats first patient with vCLAS Ultra ULTA system
Adagio Medical (ADGM) Holdings announced the treatment of the first patient with its next-generation vCLAS Ultra Ultra-Low Temperature Ablation system under Expanded Access authorization from the U.S....
Adagio Medical Treats First Patient with Faster, Single-Freeze Next-Generation ULTA System
LAGUNA HILLS, Calif.--(BUSINESS WIRE)---- $ADGM #ARRHYTHMIA--Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the tre...
Adagio Medical Holdings Transcript: AGM 2026
The meeting covered board elections and auditor ratification, with both proposals approved by a quorum of shareholders. No questions were raised, and voting results will be reported on Form 8-K within four business days.
Adagio Medical initiated with a Buy at Lucid Capital
Lucid Capital initiated coverage of Adagio Medical (ADGM) with a Buy rating and $3 price target The company created an ablation catheter that is purpose built for ventricular tachycardia, the…
Adagio Medical submits PMA application to FDA for vCLAS Ventricular Ablation
Adagio Medical (ADGM) announced the submission of its Premarket Approval, PMA, application to the U.S. Food and Drug Administration, FDA, for the vCLAS Ventricular Ablation System for the treatment of...
Adagio Medical Submits Premarket Approval Application to FDA for vCLAS® Ventricular Ablation System for the Treatment of Ventricular Tachycardia
LAGUNA HILLS, Calif.--(BUSINESS WIRE)---- $ADGM #ARRHYTHMIA--Adagio Medical Holdings, Inc (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the trea...
Adagio Medical Holdings Transcript: BofA Securities 2026 Health Care Conference
A purpose-built VT ablation catheter demonstrated strong safety and efficacy in a pivotal trial, with FDA approval expected by year-end and a next-generation device in the pipeline. The technology's all-endocardial approach and lack of irrigation offer significant clinical and operational advantages.
Adagio Medical Holdings Slides: FY 2026
Adagio Medical Holdings has posted slides in relation to its FY 2026 quarterly earnings report, which was published on May 13, 2026.
Adagio Medical Reports First Quarter 2026 Results and Meaningful Clinical Progress
LAGUNA HILLS, Calif.--(BUSINESS WIRE)---- $ADGM #ARRHYTHMIA--Adagio Medical Holdings, Inc (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the trea...
Adagio Medical Holdings Quarterly report: Q1 2026
Adagio Medical Holdings has published its Q1 2026 quarterly earnings report on May 12, 2026.
Adagio Medical Holdings Earnings release: Q1 2026
Adagio Medical Holdings released its Q1 2026 earnings on May 12, 2026, summarizing the period's financial results.
Adagio Medical Holdings Proxy statement: Proxy filing
Adagio Medical Holdings filed a proxy statement on April 30, 2026, providing details for shareholder voting and corporate governance matters.
Adagio Medical to Participate in the BofA Securities 2026 Health Care Conference
LAGUNA HILLS, Calif.--(BUSINESS WIRE)---- $ADGM #ARRHYTHMIA--Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the tre...
Adagio Medical Holdings Transcript: KOL event
FULCRUM-VT results demonstrated high safety and efficacy for ultra-low temperature ablation in challenging VT patients, with significant reductions in VT episodes and ICD shocks. The technology's procedural efficiency and adaptability support broader adoption, especially with the next-generation catheter.
Adagio Medical Holdings Slides: KOL event
Adagio Medical Holdings has posted slides in relation to its latest quarterly earnings report, which was published on April 27, 2026.
Adagio Medical reports six-month results from Fulcrum-VT IDE trial
Adagio Medical (ADGM) reported six month results from its Fulcrum-VT Investigational Device Exemption, IDE, clinical trial, which will be used to support the Company’s application for Food and Drug Ad...
Adagio Medical Announces Positive Pivotal Results for vCLAS® Ventricular Ablation System
LAGUNA HILLS, Calif.--(BUSINESS WIRE)---- $ADGM #Arrhythmia--Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the tre...
Adagio Medical's ULTA Technology to Be Featured at the Heart Rhythm 2026 Conference
LAGUNA HILLS, Calif.--(BUSINESS WIRE)--Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrh...
Adagio Medical Holdings Transcript: 25th Annual Needham Virtual Healthcare Conference
A novel ultra-low temperature VT ablation catheter is poised to transform a large, under-penetrated market, with strong clinical data, CE mark approval, and anticipated FDA approval by year-end. The company expects a two-to-three-year lead over competitors and is preparing for a focused US launch at top centers.
Adagio Medical Holdings Slides: 25th Annual Needham Virtual Healthcare Conference
Adagio Medical Holdings has posted slides in relation to its latest quarterly earnings report, which was published on April 14, 2026.
Adagio Medical initiated with an Overweight at Piper Sandler
Piper Sandler analyst Matt O’Brien initiated coverage of Adagio Medical (ADGM) with an Overweight rating and $3 price target The firm says the company has developed a novel ultra-low temperature…
Adagio Medical announces FDA granted IDE approval for FULCRUM-VT trial
Adagio Medical (ADGM) Holdings announced that the U.S. Food and Drug Administration, FDA, has granted Investigational Device Exemption, IDE, approval to expand the Company’s FULCRUM-VT trial to evalua...
Adagio Medical Receives IDE Approval from the FDA to Investigate Next-Generation vCLAS® Ventricular Ablation System
LAGUNA HILLS, Calif.--(BUSINESS WIRE)--Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrh...
Adagio Medical to Participate in the 25th Annual Needham Virtual Conference
LAGUNA HILLS, Calif.--(BUSINESS WIRE)--Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrh...
Adagio Medical Ultralow Temperature Ablation U.S. Pivotal Study Results to be Presented in Late-Breaking Session at Heart Rhythm Society 2026
LAGUNA HILLS, Calif.--(BUSINESS WIRE)--Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrh...